Levo-Dromoran

(Levorphanol)

PreclinicalSmall molecule

VValeant Pharmaceuticals

Levo-Dromoran is one of 9 small molecule programs targeting Tolerance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

ToleranceCompleted

TolerancePreclinical

Completed

Competition

Competitive Landscape

12 competitors in Tolerance

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

6 2

Fludara

Sanofi

Phase 2

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 4

Avigan

AAppili Therapeutics Inc.

Phase 2

2 5

Siplizumab

UUniversity of Alabama at Birmingham

Phase 2

1 6

Experimental

Biogen

Preclinical

1 7

Levo-Dromoran

VValeant Pharmaceuticals

Preclinical

1 8

Tazorac

FFougera Pharmaceuticals Inc.

Preclinical

1 9

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cancer1 trial

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT03579446·43 enrolled

Tolerance1 trial

Evolution of Analgesic Tolerance With Opioids

Completed·UUniversity of California, San Francisco·N/A·NCT00275249·60 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 19, 1991

LEVO-DROMORAN

NDA NDA008719

Dec 19, 1991

LEVO-DROMORAN

NDA NDA008720

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Levorphanol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levorphanol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levorphanol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA008719). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Valeant Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VValeant Pharmaceuticals

Levo-Dromoran

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cancer1 trial

Tolerance1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News